» Articles » PMID: 32097694

Expression Profile of H3K4 Demethylases with Their Clinical and Pathological Correlation in Patients with Clear Cell Renal Cell Carcinoma

Overview
Journal Gene
Specialty Molecular Biology
Date 2020 Feb 26
PMID 32097694
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Clear cell renal cell carcinoma (ccRCC) is one of the deadly diseases with poor metastatic disease prognosis. There is an urgent need to explore the potential molecular markers which can improve the prognosis of the disease. Histone demethylases have emerged as a powerful tool for cancer prognosis and therapeutics during the last decade. The implications of demethylases of histone 3 lysine 4 (H3K4) in ccRCC are however unrevealed. We therefore evaluated the expression of H3K4 demethylases in ccRCC, with emphasis on their clinical significance as a prognostic marker.

Methods: Total 50 histopathological confirmed cases of ccRCC were enrolled in the study. The expression of seven H3K4 demethylases was determined by Real-Time PCR using gene specific primers and correlated with tumor stage, grade and metastasis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the prognostic significance of H3K4 demethylases.

Results: The median age of the patients was 54 years with predominance of male patients by 2.6-fold. Among seven genes viz FBXL10, LSD1, LSD2, KDM5A, KDM5B, KDM5C and KDM5D analyzed, LSD2 was found to be significantly associated with tumor stage and metastasis. The optimal cut-off value for LSD2 was 3.2 as calculated from ROC curve analysis for metastasis as well as TNM stage with area under curve of 0.74 and 0.78 respectively. In addition, LSD2 expression showed significant positive correlation with LSD1 expression in tumor metastasis.

Conclusion: The expression of LSD2 was associated with higher TNM stage and metastasis of the tumor and thus, might serve as a useful marker for ccRCC progression.

Citing Articles

Specific regulation of BACH1 by the hotspot mutant p53 reveals a distinct gain-of-function mechanism.

Su Z, Kon N, Yi J, Zhao H, Zhang W, Tang Q Nat Cancer. 2023; 4(4):564-581.

PMID: 36973430 PMC: 10320414. DOI: 10.1038/s43018-023-00532-z.


The role of histone methylation in renal cell cancer: an update.

Hou Y, Yuan Y, Li Y, Wang L, Hu J, Liu X Mol Biol Rep. 2022; 50(3):2735-2742.

PMID: 36575323 DOI: 10.1007/s11033-022-08124-3.


KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients.

Schafer G, Bednarova N, Heidenreich A, Klocker H, Heidegger I Transl Androl Urol. 2021; 10(10):3946-3952.

PMID: 34804837 PMC: 8575572. DOI: 10.21037/tau-20-1084.


The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Angulo J, Manini C, Lopez J, Pueyo A, Colas B, Ropero S Cancers (Basel). 2021; 13(9).

PMID: 33922974 PMC: 8123355. DOI: 10.3390/cancers13092071.


Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.

Du C, Lv C, Feng Y, Yu S J Exp Clin Cancer Res. 2020; 39(1):223.

PMID: 33087165 PMC: 7576758. DOI: 10.1186/s13046-020-01735-3.